Ratio Therapeutics, Inc

Clinical Trial · NCT07156565

A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma

Overview

The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.

Phase

Phase 1

Contacts

TBD

tbd@tbd.com

ClinicalTrials.gov

NCT07156565

Drug / Compound

[Cu64]LNTH-1363S

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: NOTA

[Ac225]RTX-2358

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: Macropa™
Linker: Trillium™

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…